{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05470101",
            "orgStudyIdInfo": {
                "id": "ITI-333-003"
            },
            "organization": {
                "fullName": "Intra-Cellular Therapies, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A PET Study Following a Single Oral Dose of ITI-333 in Healthy Subjects",
            "officialTitle": "An Open-label, Positron Emission Tomography (PET) Study to Evaluate Brain Receptor Occupancy, Safety, Tolerability, and Pharmacokinetics After Single Oral Doses of ITI-333 in Healthy Subjects",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-pet-study-following-a-single-oral-dose-of-iti-in-healthy-subjects"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-07-26",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2023-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2023-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-07-20",
            "studyFirstSubmitQcDate": "2022-07-20",
            "studyFirstPostDateStruct": {
                "date": "2022-07-22",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-01-10",
            "lastUpdatePostDateStruct": {
                "date": "2023-01-11",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Intra-Cellular Therapies, Inc.",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "National Institute on Drug Abuse (NIDA)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is an open-label, single-dose study of up to 4 dose levels of ITI-333 in healthy male and female subjects. Each cohort will enroll 6 subjects. Subjects will have a baseline PET/CT scan and a postdose PET/CT scan using \\[14C\\]-MDL100907 to characterize 5-HT2A receptor occupancy"
        },
        "conditionsModule": {
            "conditions": [
                "Healthy Volunteers"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 24,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort A1: ITI-333 2.25 mg",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: ITI-333"
                    ]
                },
                {
                    "label": "Cohort A2: ITI-333 dose to be determined based on Cohort A1",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: ITI-333"
                    ]
                },
                {
                    "label": "Cohort A3: ITI-333 dose to be determined based on Cohort A1 and A2",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: ITI-333"
                    ]
                },
                {
                    "label": "Cohort A4: ITI-333 dose to be determined based on Cohort A1, A2 and A3",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: ITI-333"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ITI-333",
                    "description": "ITI-333 oral solution",
                    "armGroupLabels": [
                        "Cohort A1: ITI-333 2.25 mg",
                        "Cohort A2: ITI-333 dose to be determined based on Cohort A1",
                        "Cohort A3: ITI-333 dose to be determined based on Cohort A1 and A2",
                        "Cohort A4: ITI-333 dose to be determined based on Cohort A1, A2 and A3"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Pharmacodynamics: Receptor occupancy (RO)",
                    "timeFrame": "baseline 90-minute PET scan between Day -5 and Day -1, and a 90-minute PET scan starting at approximately 1 hour postdose"
                },
                {
                    "measure": "Pharmacokinetics: AUC0-t",
                    "description": "Area under the plasma concentration time curve from time zero to the last measurable of concentration of ITI-333 and its metabolites",
                    "timeFrame": "predose and multiple timepoints up to 24 hours postdose"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Percentage of subjects with treatment-emergent adverse events",
                    "timeFrame": "up to 30 days after last dose"
                },
                {
                    "measure": "Change from baseline in systolic and diastolic blood pressure",
                    "timeFrame": "Up to Day 7"
                },
                {
                    "measure": "Change from baseline in ECG QT interval",
                    "timeFrame": "Up to Day 7"
                },
                {
                    "measure": "Change from baseline in aspartate aminotransferase",
                    "timeFrame": "Up to Day 7"
                },
                {
                    "measure": "Change from baseline in alanine aminotransferase",
                    "timeFrame": "Up to Day 7"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Healthy male and female subjects between 18 and 45 years old (inclusive);\n* BMI inclusive of 18.0-32.0 kg/m2 at screening and a minimum weight of 50 kg;\n* Willing to be confined to the clinical research unit for the duration of the inpatient period of the study;\n\nExclusion Criteria:\n\n* Clinically significant abnormality within 2 years of Screening that in the Investigator's opinion may place the subject at risk or interfere with study outcome variables; this includes, but is not limited to, history of or current cardiac, hepatic, renal, neurologic, gastrointestinal (including history of gastric bypass), pulmonary, endocrinologic, hematologic, or immunologic disease or history of malignancy;\n* Clinically significant abnormal findings in vital sign assessments, including blood oxygen saturation (SpO2) \\< 96% and respiratory rate \\< 12 breaths per min;\n* History of psychiatric condition that in the Investigator's opinion may be detrimental to participation in the study;\n* Any condition which would preclude MRI or PET/CT examination (eg, implanted metal, claustrophobia, unable to fit in PET/CT or MRI scanners).",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "45 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "ITI Clinical Trials",
                    "role": "CONTACT",
                    "phone": "646-440-9333",
                    "email": "ITCIClinicalTrials@itci-inc.com"
                }
            ],
            "locations": [
                {
                    "facility": "Clinical Site 2",
                    "status": "RECRUITING",
                    "city": "Creve Coeur",
                    "state": "Missouri",
                    "zip": "63141",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.66089,
                        "lon": -90.42262
                    }
                },
                {
                    "facility": "Clinical Site 1",
                    "status": "RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}